336 related articles for article (PubMed ID: 16199884)
41. Development of zinc finger domains for recognition of the 5'-ANN-3' family of DNA sequences and their use in the construction of artificial transcription factors.
Dreier B; Beerli RR; Segal DJ; Flippin JD; Barbas CF
J Biol Chem; 2001 Aug; 276(31):29466-78. PubMed ID: 11340073
[TBL] [Abstract][Full Text] [Related]
42. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
Huang X; Gao L; Wang S; Lee CK; Ordentlich P; Liu B
Cancer Res; 2009 Nov; 69(21):8403-11. PubMed ID: 19826038
[TBL] [Abstract][Full Text] [Related]
43. Role of erbB3 receptors in cancer therapeutic resistance.
Lee Y; Ma J; Lyu H; Huang J; Kim A; Liu B
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):190-8. PubMed ID: 24449784
[TBL] [Abstract][Full Text] [Related]
44. Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.
Stoll SW; Kansra S; Peshick S; Fry DW; Leopold WR; Wiesen JF; Sibilia M; Zhang T; Werb Z; Derynck R; Wagner EF; Elder JT
Neoplasia; 2001; 3(4):339-50. PubMed ID: 11571634
[TBL] [Abstract][Full Text] [Related]
45. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.
Gilbertson RJ; Bentley L; Hernan R; Junttila TT; Frank AJ; Haapasalo H; Connelly M; Wetmore C; Curran T; Elenius K; Ellison DW
Clin Cancer Res; 2002 Oct; 8(10):3054-64. PubMed ID: 12374672
[TBL] [Abstract][Full Text] [Related]
46. Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity.
Kozloski GA; Carraway CA; Carraway KL
J Cell Physiol; 2010 Sep; 224(3):649-57. PubMed ID: 20432461
[TBL] [Abstract][Full Text] [Related]
47. Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.
Aurisicchio L; Marra E; Luberto L; Carlomosti F; De Vitis C; Noto A; Gunes Z; Roscilli G; Mesiti G; Mancini R; Alimandi M; Ciliberto G
J Cell Physiol; 2012 Oct; 227(10):3381-8. PubMed ID: 22213458
[TBL] [Abstract][Full Text] [Related]
48. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
49. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b.
Scott GK; Goga A; Bhaumik D; Berger CE; Sullivan CS; Benz CC
J Biol Chem; 2007 Jan; 282(2):1479-86. PubMed ID: 17110380
[TBL] [Abstract][Full Text] [Related]
50. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.
Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J
Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598
[TBL] [Abstract][Full Text] [Related]
51. Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells.
Darcy KM; Zangani D; Wohlhueter AL; Huang RY; Vaughan MM; Russell JA; Ip MM
J Histochem Cytochem; 2000 Jan; 48(1):63-80. PubMed ID: 10653587
[TBL] [Abstract][Full Text] [Related]
52. Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.
Wandinger SK; Lahortiga I; Jacobs K; Klammer M; Jordan N; Elschenbroich S; Parade M; Jacoby E; Linders JT; Brehmer D; Cools J; Daub H
PLoS One; 2016; 11(1):e0146100. PubMed ID: 26745281
[TBL] [Abstract][Full Text] [Related]
53. APIP, an ERBB3-binding partner, stimulates erbB2-3 heterodimer formation to promote tumorigenesis.
Hong SH; Lee WJ; Kim YD; Kim H; Jeon YJ; Lim B; Cho DH; Heo WD; Yang DH; Kim CY; Yang HK; Yang JK; Jung YK
Oncotarget; 2016 Apr; 7(16):21601-17. PubMed ID: 26942872
[TBL] [Abstract][Full Text] [Related]
54. Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells.
Belleudi F; Marra E; Mazzetta F; Fattore L; Giovagnoli MR; Mancini R; Aurisicchio L; Torrisi MR; Ciliberto G
Cell Cycle; 2012 Apr; 11(7):1455-67. PubMed ID: 22421160
[TBL] [Abstract][Full Text] [Related]
55. Expression, localization, and regulation of the neuregulin receptor ErbB3 in mouse heart.
Campreciós G; Lorita J; Pardina E; Peinado-Onsurbe J; Soley M; Ramírez I
J Cell Physiol; 2011 Feb; 226(2):450-5. PubMed ID: 20672328
[TBL] [Abstract][Full Text] [Related]
56. Muc4 is required for activation of ErbB2 in signet ring carcinoma cell lines.
Yokoyama A; Shi BH; Kawai T; Konishi H; Andoh R; Tachikawa H; Ihara S; Fukui Y
Biochem Biophys Res Commun; 2007 Mar; 355(1):200-3. PubMed ID: 17292332
[TBL] [Abstract][Full Text] [Related]
57. ErbB2, ErbB3 and ErbB4 expression in urothelial tumors of the upper urinary tract and their prognostic significance.
Galanakis I; Spyropoulos E; Gkialas I; Nomikos A; Souka E; Mitropoulos D
J BUON; 2013; 18(3):653-9. PubMed ID: 24065479
[TBL] [Abstract][Full Text] [Related]
58. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Wang S; Huang X; Lee CK; Liu B
Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
[TBL] [Abstract][Full Text] [Related]
59. Knockout of all ErbB-family genes delineates their roles in proliferation, survival and migration.
Matsuda K; Hirayama D; Hino N; Kuno S; Sakaue-Sawano A; Miyawaki A; Matsuda M; Terai K
J Cell Sci; 2023 Aug; 136(16):. PubMed ID: 37519219
[TBL] [Abstract][Full Text] [Related]
60. Expression and differential signaling of heregulins in pancreatic cancer cells.
Kolb A; Kleeff J; Arnold N; Giese NA; Giese T; Korc M; Friess H
Int J Cancer; 2007 Feb; 120(3):514-23. PubMed ID: 17096356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
